Zelgen Biopharmaceuticals: Application for the third indication of gecacitinib hydrochloride accepted

Zelgen Biopharmaceuticals announced that the New Drug Application for its gecacitinib hydrochloride tablets for the treatment of active ankylosing spondylitis has recently been accepted by the National Medical Products Administration. This is the third indication for which the drug has applied for new drug marketing approval, with acceptance number CXHS2600137.